David Risinger Analyst Performance

Senior Managing Director & Senior Research Analyst at Leerink Partners

David Risinger is a stock analyst at Leerink Partners in the medical sector, covering 24 publicly traded companies. Over the past year, David Risinger has issued 8 stock ratings, including buy and hold recommendations. While full access to David Risinger's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Risinger's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

147 Last 10 Years

Buy Recommendations

42.47% 62 Buy Ratings

Companies Covered

24 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	42.5%	62 ratings
Hold	51.4%	75 ratings
Sell	6.2%	9 ratings

Out of 146 total stock ratings issued by David Risinger at Leerink Partners, the majority (51.4%) have been Hold recommendations, followed by 42.5% Buy and 6.2% Sell.

Best & Worst Calls

• Best Call

  000.0%

  AGN

  Dec 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  BHC

  Jul 2015

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NYSE	58.3% of companies on NYSE	14 companies
NASDAQ	41.7% of companies on NASDAQ	10 companies

David Risinger, an analyst at Leerink Partners, currently covers 24 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 24 companies	100.0%

David Risinger of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	29.2%
LARGE CAP PHARMA 5 companies	20.8%
PHARMACEUTICAL PREPARATIONS 5 companies	20.8%
MED - GENERIC DRG 2 companies	8.3%
MED PRODUCTS 2 companies	8.3%
MED - DRUGS 1 company	4.2%
MED - OUTP/HM CRE 1 company	4.2%
MEDICAL SERVICES 1 company	4.2%

About David Risinger

David Risinger, CFA is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Diversified Biopharmaceuticals. Prior to joining the Firm in 2022, David’s most recent Wall Street role was Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to Morgan Stanley, he was head of Global Healthcare Research and Senior US Pharmaceutical analyst at Merrill Lynch & Co. He started his Wall Street career at Dillon, Read & Co. He has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021. He earned his Bachelor of Arts in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.

Follow on LinkedIn

David Risinger's Ratings History at Leerink Partners

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
VRTX Vertex Pharmaceuticals	9/25/2025	Upgrade	$376.62	$456.00	Outperform	$0.00 00.00% ROI
MTSR Metsera	9/24/2025	Reiterated Rating	$52.95	$57.00	Market Perform	$0.00 00.00% ROI
ROIV Roivant Sciences	9/18/2025	Boost Price Target	$15.28	$22.00	Outperform	$0.00 00.00% ROI
MTSR Metsera	9/9/2025	Initiated Coverage	$35.10	$77.00	Outperform	$0.00 00.00% ROI
JNJ Johnson & Johnson	5/13/2025	Downgrade	$153.88	$153.00	Market Perform	$0.00 00.00% ROI
VRTX Vertex Pharmaceuticals	5/6/2025	Reiterated Rating	$500.19	$503.00	Market Perform	$0.00 00.00% ROI
REGN Regeneron Pharmaceuticals	2/5/2025	Upgrade	$697.05	$834.00	Outperform	$0.00 00.00% ROI
JNJ Johnson & Johnson	1/23/2025	Lower Price Target	$146.81	$169.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.